AngioDynamics, Inc.

As of May 31, 2026, AngioDynamics, Inc. carries a market capitalization of 410.75M, placing it among publicly traded companies globally. Its enterprise value stands at 364.54M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

AngioDynamics, Inc.'s next confirmed earnings release is scheduled for January 7, 2027.

As of May 31, 2026, AngioDynamics, Inc. has 41.70M shares outstanding.

These figures are as of May 31, 2026. The price-to-sales ratio is 1.49, and the price-to-book ratio stands at 2.80.

These figures are as of May 31, 2026. The EV/Sales ratio of 1.33 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 364.54M versus a market cap of 410.75M, with the gap driven by net debt and cash on the balance sheet.

As of May 31, 2026, AngioDynamics, Inc. maintains a current ratio of 2.19, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended May 31, 2026, AngioDynamics, Inc. posted a negative return on equity (ROE) of -20.77, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -13.43, reflecting losses generated across the asset base. The company generates approximately 413,466.70 in revenue per employee across its workforce of 664.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.54 indicates how many times AngioDynamics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended May 31, 2026, AngioDynamics, Inc. recorded 379,147.60 in income tax expense. The company reported a pretax loss of -31.14M and -31.52M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, AngioDynamics, Inc.'s stock has gained approximately 2.88% over the past 52 weeks. The 50-day moving average sits at 12.74, while the 200-day moving average is 10.78.

Over the twelve months ended May 31, 2026, AngioDynamics, Inc. generated 274.65M in revenue and converted that into -31.52M in net income, yielding earnings per share of -0.76. EBITDA reached -14.56M, while operating income came in at -19.15M.

These figures are as of May 31, 2026. Total book value stands at 146.53M, with working capital of 76.07M providing operational flexibility.

AngioDynamics, Inc. produced 2.65M in operating cash flow over the twelve months ended May 31, 2026. After subtracting -2.21M in capital expenditures, free cash flow totaled 435,762.40 - equivalent to 0.01 per share.

Over the twelve months ended May 31, 2026, AngioDynamics, Inc. posted a gross margin of 54.62, reflecting its pricing power and cost economics. The operating margin of -6.97 and net profit margin of -11.48 provide insight into operational efficiency.

These figures cover the twelve months ended May 31, 2026. Free cash flow yield stands at 0.11, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.12, meaning AngioDynamics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of May 31, 2026, AngioDynamics, Inc. has an Altman Z-Score of 1.48, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.